Safety of Ferric Carboxymaltose Immediately after Infliximab Administration, in a Single Session, in Inflammatory Bowel Disease Patients with Iron Deficiency: A Pilot Study

AIM: To obtain preliminary safety and efficacy data on intravenous (IV) administration of infliximab (IFX) and ferric carboxymaltose (FCM) to inflammatory bowel disease (IBD) patients in a single treatment session. METHODS: A two-phase non-interventional, observational, prospective pilot study was p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortes, Xavier, Borrás-Blasco, Joaquín, Molés, Jose Ramón, Boscá, Maia, Cortés, Ernesto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443970/
https://www.ncbi.nlm.nih.gov/pubmed/26011514
http://dx.doi.org/10.1371/journal.pone.0128156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443970/
https://www.ncbi.nlm.nih.gov/pubmed/26011514
http://dx.doi.org/10.1371/journal.pone.0128156

Ejemplares similares